AMPEL BioSolutions

Press Release on breakthrough study with @wakeforestmed prnewswire.com/news-releases/…

Link to breakthrough study demonstrating blood test to predict susceptibility to cardiovascular events published today in @CellRepMed cell.com/cell-reports-m…

@AMPELBio collaborating w/ @wakeforestmed published breakthrough study in @CellRepMed fueling a #precisionmedicine #CardioGENE blood test to predict #genetic susceptibility to #cardiovascular events even w/o traditional risk factors of smoking, high fat diet & sedentary lifestyle

AMPEL BioSolutions’ new genomics CovGENE product proves to have 90%+ accuracy in predicting severity of COVID-19 in positive patients. prn.to/3dfSfFX @AmrieAMPEL #COVID19 #SARS-Cov2 #personalizedmedicine #GeneExpression

We're excited to announce a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer prn.to/3OLpm1R

Online now! An introduction to machine learning and analysis of its use in rheumatic diseases #RheumTwitter #rheumatology #MachineLearning #MedEd go.nature.com/3q3gL0T

Dr. Grammer to introduce one of AMPEL’s products expected to commercialize in 2022. LuGENE®, a CLIA-certified blood test for patients/physicians, assesses disease state/flares and best drug options for lupus patients. prn.to/3AgdKg0

Thank you @vabio @Va_DrugDisc for the opportunity to speak today on the prediction of COVID 19 disease severity and best drug options for patients at the symposium on "Coronavirus: Present and Future

@AmrieAMPEL will be giving a flash talk today at 2:45PM EDT at the Tom Tom Festival. The talk will be on Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data. rb.gy/orzqcc

Informative webinar on June 23 featuring AMPEL's own @AmrieAMPEL! Click here to register: eventbrite.com/e/a-conversati…

Tonight @NBC29 at 5 & 6 will air a discussion on @AMPELBio technology that identifies medicines to blunt lung damage experienced by severe #Covid_19 patients with AMPEL CSO @AmrieAMPEL Tune in Tonight! @BioHealthCR @VanHipp @katevega20

AMPEL is looking for licensing partners to bring it's Covid19 prognostic to market and for scientists with validation datasets to collaborate! #Covid19 @AmrieAMPEL @VanHipp @katevega20 wina.com/podcasts/charl

CovGENE: AMPEL’s Novel Prognostic Technology Predicts Severity of Illness in COVID19 Patients and Identifies Treatments. learn more ampelbiosolutions.com/covgene #COVIDResearch #covgene prn.to/3f1WKPq

@AMPELBio announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic at the Biotech Showcase at JP Morgan Healthcare #personalizedmedicine #precisionmedicine #permedcoalition #lupus #SLE prn.to/36ZhQul

AMPEL BioSolutions is at the VCU career fair today, booth 50. Stop by and learn more about our opportunities. @VCU @VCAENGR @VCU_CCTR #MachineLearning #BioInformatics #internships #AI #researcher #immunology #lupus #autoimmunedisease

Nice write up on AMPEL's work on interferons in Lupus, led by Senior Scientist Michelle Catalina. #ai #lupus #machinelearning the-rheumatologist.org/article/multip…

@AmrieAMPEL will be on NBC29 tonight at 5 & 6:00PM News sharing more about AMPEL's breakthrough news nbc29.com/story/40760325… #lupus #BigData #BigDataAnalytics #MachineLearning #AI #GENE #innovation #personalizedmedicine

@kgmaeda_g Ampel’s promising breakthrough is the news patients have desperately been waiting to hear. We applaud Ampel BioSolutions’s goal to help identify patients’ disease activity in real time. nature.com/articles/s4159…

Dr. Amrie Grammer of AMPEL BioSolutions joins host Rich Bendis on BioTalk dlvr.it/R81z6x

Dr. @AmrieGrammer of AMPEL BioSolutions joins Rich on a new episode of BioTalk. Listen now on iTunes (apple.co/2LGI6Sp), Google Play (bit.ly/2JnfxI9), and TuneIn (bit.ly/2JnfxI9).